[Clinical characteristics and outcomes of elderly patients with stage Ⅰ diffuse large B-cell lymphoma: a study by the Jiangsu Cooperative Lymphoma Group (JCLG)].

Y Xia, J He, W Y Gu, T Jia, T X Lu, Y L Li, J H Zhou, B Z Li, H Y Hua, P Liu, Y Q Miao, Y X Cheng, X Y Xie, Y P Zhang, W Z Wu, Z X Jia, X Z Lu, C L Wang, L Yu, M Xu, J N Shi, W F Chen, W C Zhuang, Z Qian, J Qian, H W Ni, Y F Chen, Q D Shen, J Y Li, W Y Shi
{"title":"[Clinical characteristics and outcomes of elderly patients with stage Ⅰ diffuse large B-cell lymphoma: a study by the Jiangsu Cooperative Lymphoma Group (JCLG)].","authors":"Y Xia, J He, W Y Gu, T Jia, T X Lu, Y L Li, J H Zhou, B Z Li, H Y Hua, P Liu, Y Q Miao, Y X Cheng, X Y Xie, Y P Zhang, W Z Wu, Z X Jia, X Z Lu, C L Wang, L Yu, M Xu, J N Shi, W F Chen, W C Zhuang, Z Qian, J Qian, H W Ni, Y F Chen, Q D Shen, J Y Li, W Y Shi","doi":"10.3760/cma.j.cn112138-20241219-00837","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To summarize the clinical characteristics of elderly patients with stage Ⅰ diffuse large B-cell lymphoma (DLBCL) and analyze the factors associated with prognosis. <b>Methods:</b> A case series study was conducted by retrospectively collecting clinical data from patients aged over 60 years with newly diagnosed stage Ⅰ DLBCL across 20 medical centers in Jiangsu Province, China, between June 2010 and April 2023. The involved site, classification and treatment plan were summarized. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Statistical analyses were performed using the Kaplan-Meier method, and Cox regression model. <b>Results:</b> The study included 255 patients with a median age of 69 years, of whom 130 (51.0%) were male, 66 (25.9%) were aged ≥75 years and 26 (10.1%) had a high Charlson Comorbidity Index (CCI) score of ≥2. Extranodal involvement was observed in 163 (63.9%) patients, with the stomach (37.4%, 61/163), intestine (19.0%, 31/163), testes (11.0%, 18/163), and breast (7.4%, 12/163) being the most frequently affected sites. The non-germinal center B-cell (non-GCB) subtype was prevalent in 63.7% of patients (142/223), with no significant difference between the nodal and extranodal groups (<i>P</i>=0.681). Furthermore, 73.9% (184/249) and 11.7% (29/249) of patients received the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-miniCHOP regimen, respectively. The overall 3-year PFS rate was 81.5%, and the 3-year OS rate was 85.6%. Patients aged ≥75 years (<i>HR</i>=2.910, 95%<i>CI</i> 1.565-5.408, <i>P</i>=0.001) and/or with a CCI score ≥2 (<i>HR</i>=2.324, 95%<i>CI</i> 1.141-4.732, <i>P</i>=0.020) had a significantly poorer PFS. Incorporating age ≥75 years and CCI score ≥2 into the stage-modified international prognostic index (sm-IPI) can better stratify the prognosis of elderly patients with stage Ⅰ DLBCL. The 3-year PFS rate was 48.7% in the high-risk group versus 85.7% in the low-risk group (<i>P</i><0.001). <b>Conclusions:</b> Our findings show that the elderly patients with stage Ⅰ DLBCL were predominantly characterized by extranodal involvement (particularly in the stomach and intestinal tract) and non-GCB subtype. Age ≥75 years and CCI ≥2 were identified as independent prognostic factors. The newly established sm-IPI-75-CCI incorporating these factors demonstrated superior prognostic discrimination compared to conventional risk assessment systems.</p>","PeriodicalId":68309,"journal":{"name":"中华内科杂志","volume":"64 6","pages":"504-513"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华内科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112138-20241219-00837","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To summarize the clinical characteristics of elderly patients with stage Ⅰ diffuse large B-cell lymphoma (DLBCL) and analyze the factors associated with prognosis. Methods: A case series study was conducted by retrospectively collecting clinical data from patients aged over 60 years with newly diagnosed stage Ⅰ DLBCL across 20 medical centers in Jiangsu Province, China, between June 2010 and April 2023. The involved site, classification and treatment plan were summarized. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Statistical analyses were performed using the Kaplan-Meier method, and Cox regression model. Results: The study included 255 patients with a median age of 69 years, of whom 130 (51.0%) were male, 66 (25.9%) were aged ≥75 years and 26 (10.1%) had a high Charlson Comorbidity Index (CCI) score of ≥2. Extranodal involvement was observed in 163 (63.9%) patients, with the stomach (37.4%, 61/163), intestine (19.0%, 31/163), testes (11.0%, 18/163), and breast (7.4%, 12/163) being the most frequently affected sites. The non-germinal center B-cell (non-GCB) subtype was prevalent in 63.7% of patients (142/223), with no significant difference between the nodal and extranodal groups (P=0.681). Furthermore, 73.9% (184/249) and 11.7% (29/249) of patients received the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-miniCHOP regimen, respectively. The overall 3-year PFS rate was 81.5%, and the 3-year OS rate was 85.6%. Patients aged ≥75 years (HR=2.910, 95%CI 1.565-5.408, P=0.001) and/or with a CCI score ≥2 (HR=2.324, 95%CI 1.141-4.732, P=0.020) had a significantly poorer PFS. Incorporating age ≥75 years and CCI score ≥2 into the stage-modified international prognostic index (sm-IPI) can better stratify the prognosis of elderly patients with stage Ⅰ DLBCL. The 3-year PFS rate was 48.7% in the high-risk group versus 85.7% in the low-risk group (P<0.001). Conclusions: Our findings show that the elderly patients with stage Ⅰ DLBCL were predominantly characterized by extranodal involvement (particularly in the stomach and intestinal tract) and non-GCB subtype. Age ≥75 years and CCI ≥2 were identified as independent prognostic factors. The newly established sm-IPI-75-CCI incorporating these factors demonstrated superior prognostic discrimination compared to conventional risk assessment systems.

[老年Ⅰ期弥漫性大b细胞淋巴瘤患者的临床特点及转归:江苏省淋巴瘤合作组的研究]。
目的:总结老年Ⅰ期弥漫性大b细胞淋巴瘤(DLBCL)患者的临床特点,分析影响预后的因素。方法:回顾性收集2010年6月至2023年4月中国江苏省20个医疗中心60岁以上新诊断为Ⅰ期DLBCL患者的临床资料,进行病例系列研究。综述了累及部位、分类及治疗方案。主要终点为无进展生存期(PFS)和总生存期(OS)。采用Kaplan-Meier法和Cox回归模型进行统计分析。结果:研究纳入255例患者,中位年龄69岁,其中男性130例(51.0%),年龄≥75岁66例(25.9%),CCI评分≥2的26例(10.1%)。163例(63.9%)患者出现结外受累,其中胃(37.4%,61/163)、肠(19.0%,31/163)、睾丸(11.0%,18/163)和乳腺(7.4%,12/163)是最常见的受累部位。非生发中心b细胞(non-GCB)亚型在63.7%的患者中普遍存在(142/223),淋巴结组和结外组之间无显著差异(P=0.681)。73.9%(184/249)和11.7%(29/249)的患者分别接受了R-CHOP(利妥昔单抗、环磷酰胺、阿霉素、长春新碱、泼尼松)和R-miniCHOP方案。总体3年PFS为81.5%,3年OS为85.6%。年龄≥75岁(HR=2.910, 95%CI 1.565-5.408, P=0.001)和/或CCI评分≥2 (HR=2.324, 95%CI 1.141-4.732, P=0.020)的患者PFS明显较差。将年龄≥75岁、CCI评分≥2纳入分期修正国际预后指数(sm-IPI)可以更好地对老年Ⅰ期DLBCL患者的预后进行分层。高危组3年PFS率为48.7%,低危组为85.7%(结论:我们的研究结果表明,老年Ⅰ期DLBCL患者主要以结外累及(特别是在胃和肠道)和非gcb亚型为特征。年龄≥75岁和CCI≥2被认为是独立的预后因素。与传统的风险评估系统相比,新建立的纳入这些因素的sm-IPI-75-CCI显示出更好的预后辨别能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
19688
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信